Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19788) 19788
Newsletter (210) 210
Newspaper Article (70) 70
Magazine Article (33) 33
Book Chapter (27) 27
Dissertation (15) 15
Transcript (6) 6
Conference Proceeding (5) 5
Publication (5) 5
Web Resource (2) 2
Book Review (1) 1
Journal / eJournal (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17735) 17735
antineoplastic combined chemotherapy protocols - therapeutic use (11406) 11406
female (11190) 11190
vincristine - administration & dosage (11183) 11183
male (11092) 11092
science & technology (10187) 10187
life sciences & biomedicine (10034) 10034
middle aged (7985) 7985
adult (7538) 7538
cyclophosphamide - administration & dosage (7401) 7401
doxorubicin - administration & dosage (6733) 6733
aged (5922) 5922
oncology (5629) 5629
vincristine - therapeutic use (5339) 5339
biological and medical sciences (5327) 5327
medical sciences (5297) 5297
prednisone - administration & dosage (5185) 5185
chemotherapy (4990) 4990
adolescent (3911) 3911
cyclophosphamide - therapeutic use (3650) 3650
antineoplastic combined chemotherapy protocols - administration & dosage (3563) 3563
vincristine (3531) 3531
treatment outcome (3348) 3348
combined modality therapy (3347) 3347
hematology (3276) 3276
prognosis (3103) 3103
doxorubicin - therapeutic use (3030) 3030
child (2970) 2970
prednisone - therapeutic use (2891) 2891
antineoplastic combined chemotherapy protocols - adverse effects (2857) 2857
pharmacology. drug treatments (2755) 2755
antineoplastic agents (2704) 2704
vincristine - adverse effects (2529) 2529
cancer (2370) 2370
methotrexate - administration & dosage (2359) 2359
child, preschool (2270) 2270
abridged index medicus (2232) 2232
remission induction (2128) 2128
etoposide - administration & dosage (2088) 2088
lymphoma, large b-cell, diffuse - drug therapy (1889) 1889
neoplasm staging (1833) 1833
bleomycin - administration & dosage (1823) 1823
retrospective studies (1815) 1815
follow-up studies (1804) 1804
lymphoma, non-hodgkin - drug therapy (1771) 1771
drug therapy, combination (1715) 1715
rituximab (1708) 1708
disease-free survival (1673) 1673
survival rate (1586) 1586
hematologic and hematopoietic diseases (1574) 1574
cyclophosphamide - adverse effects (1501) 1501
aged, 80 and over (1490) 1490
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (1485) 1485
infant (1476) 1476
procarbazine - administration & dosage (1468) 1468
hodgkin disease - drug therapy (1463) 1463
doxorubicin - adverse effects (1399) 1399
drug administration schedule (1334) 1334
prednisolone - administration & dosage (1334) 1334
survival analysis (1329) 1329
time factors (1325) 1325
cyclophosphamide (1291) 1291
tumors (1289) 1289
animals (1254) 1254
lymphoma (1242) 1242
care and treatment (1239) 1239
prednisone - adverse effects (1226) 1226
antineoplastic agents - therapeutic use (1225) 1225
cisplatin - administration & dosage (1186) 1186
doxorubicin (1140) 1140
cytarabine - administration & dosage (1139) 1139
pediatrics (1117) 1117
lymphomas (1104) 1104
antineoplastic combined chemotherapy protocols (1056) 1056
methotrexate - therapeutic use (972) 972
young adult (964) 964
vincristine - pharmacology (961) 961
dactinomycin - administration & dosage (933) 933
dexamethasone - administration & dosage (925) 925
prospective studies (914) 914
lymphoma, large b-cell, diffuse - pathology (901) 901
antineoplastic agents - administration & dosage (899) 899
lung neoplasms - drug therapy (893) 893
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (882) 882
clinical trials as topic (879) 879
antibodies, monoclonal, murine-derived (846) 846
risk factors (804) 804
lymphoma - drug therapy (781) 781
dacarbazine - administration & dosage (778) 778
prednisone (777) 777
medicine & public health (775) 775
recurrence (759) 759
mechlorethamine - administration & dosage (735) 735
research (725) 725
patients (707) 707
radiotherapy (699) 699
tomography, x-ray computed (692) 692
lymphoma, b-cell - drug therapy (678) 678
dose-response relationship, drug (672) 672
analysis (668) 668
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17752) 17752
Japanese (1108) 1108
German (464) 464
French (376) 376
Chinese (359) 359
Spanish (259) 259
Russian (236) 236
Polish (177) 177
Italian (97) 97
Portuguese (51) 51
Hungarian (28) 28
Dutch (18) 18
Czech (13) 13
Hebrew (11) 11
Danish (10) 10
Croatian (9) 9
Serbian (8) 8
Korean (7) 7
Finnish (5) 5
Ukrainian (5) 5
Bulgarian (4) 4
Romanian (4) 4
Turkish (4) 4
Lithuanian (2) 2
Swedish (2) 2
Bosnian (1) 1
Norwegian (1) 1
Persian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
by Horwitz, Steven and O'Connor, Owen A and Pro, Barbara and Illidge, Tim and Fanale, Michelle and Advani, Ranjana and Bartlett, Nancy L and Christensen, Jacob Haaber and Morschhauser, Franck and Domingo-Domenech, Eva and Rossi, Giuseppe and Kim, Won Seog and Feldman, Tatyana and Lennard, Anne and Belada, David and Illés, Árpád and Tobinai, Kensei and Tsukasaki, Kunihiro and Yeh, Su-Peng and Shustov, Andrei and Hüttmann, Andreas and Savage, Kerry J and Yuen, Sam and Iyer, Swaminathan and Zinzani, Pier Luigi and Hua, Zhaowei and Little, Meredith and Rao, Shangbang and Woolery, Joseph and Manley, Thomas and Trümper, Lorenz and Aboulafia, David and Advani, Ranjana and Alpdogan, Onder and Ando, Kiyoshi and Arcaini, Luca and Baldini, Luca and Bellam, Naresh and Bartlett, Nancy and Belada, David and Yehuda, Dina Ben and Benedetti, Fabio and Borchman, Peter and Bordessoule, Dominique and Brice, Pauline and Briones, Javier and Caballero, Dolores and Carella, Angelo Michele and Chang, Hung and Cheong, June Weon and Cho, Seok-Goo and Choi, Ilseung and Choquet, Sylvain and Colita, Andrei and Congui, Angela Giovanna and D'amore, Francesco and Dang, Nam and Davison, Kelly and de Guibert, Sophie and Brown, Peter de Nully and Delwail, Vincent and Demeter, Judit and di Raimondo, Francesco and Do, Young Rok and Domingo, Eva and Douvas, Michael and Dreyling, Martin and Ernst, Thomas and Fanale, Michelle and Fay, Keith and Feldman, Tatyana and Ferrero, Silvia Fernandez and Flinn, Ian Winchester and Forero-Torres, Andres and Fox, Christopher and Friedberg, Jonathan and Fukuhara, Noriko and Garcia-Marco, Jose and Cruz, Jorge Gayoso and Codina, Jose Gomez and Gressin, Remy and Grigg, Andrew and Gurion, Ronit and Christensen, Jacob Haaber and Haioun, Corinne and Hajek, Roman and Hanel, Mathias and Hatake, Kiyohiko and Hensen, Robert and Horowitz, Netanel and Horwitz, Steven and Huttmann, Andreas and Illes, Arpad and Illidge, Tim and Ishizawa, Kenichi and Islas-Ohlmayer, Miguel and Jacobsen, Eric and Janakiram, Murali and Jurczak, Wojciech and Kaminski, Mark and ... and ECHELON-2 Study Group and ECHELON 2 Study Grp
The Lancet (British edition), ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 229 - 240
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Double-Blind Method | Humans | Middle Aged | Immunologic Factors - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Immunoconjugates - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Large-Cell, Anaplastic - drug therapy | Intention to Treat Analysis | Vincristine - administration & dosage | Adult | Female | Aged | Immunologic Factors - adverse effects | Brentuximab Vedotin | Doxorubicin - administration & dosage | Immunoconjugates - adverse effects | Leukemia | Clinical trials | Lymphocytes T | Peripheral neuropathy | Cancer therapies | Doxorubicin | Evidence-based medicine | Regulatory approval | Randomization | CD30 antigen | Safety management | Genetics | Safety | Active control | Neutropenia | Cell survival | Prednisone | Patients | Survival | Vincristine | Lymphoma | Cyclophosphamide | Chemotherapy | Medical prognosis | Adults | Interferon | Anaplastic large-cell lymphoma | T-cell lymphoma | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
by Pfreundschuh, Michael and Trümper, Lorenz and Österborg, Anders and Pettengell, Ruth and Trneny, Marek and Imrie, Kevin and Ma, David and Gill, Devinder and Walewski, Jan and Zinzani, Pier-Luigi and Stahel, Rolf and Kvaloy, Stein and Shpilberg, Ofer and Jaeger, Ulrich and Hansen, Mads and Lehtinen, Tuula and López-Guillermo, Armando and Corrado, Claudia and Scheliga, Adriana and Milpied, Noel and Mendila, Myriam and Rashford, Michelle and Kuhnt, Evelyn and Loeffler, Markus and for the MabThera International Trial (MInT) Group and MInT Grp and MabThera International Trial Group
The lancet oncology, ISSN 1470-2045, 2006, Volume 7, Issue 5, pp. 379 - 391
Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Murine-Derived | Prognosis | Humans | Lymphoma, B-Cell - diagnosis | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Rituximab | Antibodies, Monoclonal - therapeutic use | Survival Rate | Treatment Outcome | Antineoplastic Agents - therapeutic use | Prednisone | Doxorubicin | Vincristine | Disease-Free Survival | Cyclophosphamide | Adolescent | Adult | Lymphoma, B-Cell - drug therapy | Lymphoma, Non-Hodgkin - diagnosis | Lymphoma, Non-Hodgkin - drug therapy | Medical colleges | Chemotherapy | Anthracyclines | Corticosteroids | Clinical trials | Lymphomas | Cancer | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
by Schmitz, Norbert, Prof and Nickelsen, Maike, MD and Ziepert, Marita, PhD and Haenel, Mathias, MD and Borchmann, Peter, MD and Schmidt, Christian, MD and Viardot, Andreas, MD and Bentz, Martin, MD and Peter, Norma, MD and Ehninger, Gerhard, Prof and Doelken, Gottfried, Prof and Ruebe, Christian, Prof and Truemper, Lorenz, Prof and Rosenwald, Andreas, Prof and Pfreundschuh, Michael, Prof and Loeffler, Markus, Prof and Glass, Bertram, MD and for the German High-Grade Lymphoma Study Group (DSHNHL) and German High-Grade Lymphoma Study G and German High-Grade Lymphoma Study Group (DSHNHL)
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1250 - 1259
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Rituximab | Etoposide - administration & dosage | Male | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Antimitotic agents | Chemotherapy | Stem cells | Dosage and administration | Product development | Transplantation | Lymphomas | Antineoplastic agents | Cancer | Medical informatics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis
by Jabbour, Elias J and Sasaki, Koji and Ravandi, Farhad and Short, Nicholas J and Garcia‐Manero, Guillermo and Daver, Naval and Kadia, Tapan and Konopleva, Marina and Jain, Nitin and Cortes, Jorge and Issa, Ghayas C and Jacob, Jovitta and Kwari, Monica and Thompson, Philip and Garris, Rebecca and Pemmaraju, Naveen and Yilmaz, Musa and O’Brien, Susan M and Kantarjian, Hagop M
Cancer, ISSN 0008-543X, 08/2019, Volume 125, Issue 15, pp. 2579 - 2586
inotuzumab | older acute lymphoblastic leukemia (ALL) | blinatumomab | outcome | mini‐hyperfractionated cyclophosphamide, vincristine, and dexamethasone (mini‐HCVD) | Life Sciences & Biomedicine | Oncology | Science & Technology | Inotuzumab Ozogamicin - therapeutic use | Inotuzumab Ozogamicin - pharmacology | Antibodies, Bispecific - pharmacology | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Survival Rate | Antineoplastic Agents, Immunological - pharmacology | Antibodies, Bispecific - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Propensity Score | Antineoplastic Agents, Immunological - therapeutic use | Aged, 80 and over | Female | Aged | Dexamethasone | Acute lymphatic leukemia | Leukemia | Antibodies | Lymphatic leukemia | Multivariate analysis | Survival | Doxorubicin | Vincristine | Philadelphia chromosome | Matching | Cyclophosphamide | Chemotherapy | Medical prognosis | Remission | Chromosomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
by Chiappella, Annalisa and Martelli, Maurizio and Angelucci, Emanuele and Brusamolino, Ercole and Evangelista, Andrea and Carella, Angelo Michele and Stelitano, Caterina and Rossi, Giuseppe and Balzarotti, Monica and Merli, Francesco and Gaidano, Gianluca and Pavone, Vincenzo and Rigacci, Luigi and Zaja, Francesco and D'Arco, Alfonso and Cascavilla, Nicola and Russo, Eleonora and Castellino, Alessia and Gotti, Manuel and Congiu, Angela Giovanna and Cabras, Maria Giuseppina and Tucci, Alessandra and Agostinelli, Claudio and Ciccone, Giovannino and Pileri, Stefano A and Vitolo, Umberto
The lancet oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
by Engert, Andreas, MD and Haverkamp, Heinz, PhD and Kobe, Carsten, MD and Markova, Jana, MD and Renner, Christoph, MD and Ho, Antony, MD and Zijlstra, Josée, MD and Král, Zdenek, MD and Fuchs, Michael, MD and Hallek, Michael, MD and Kanz, Lothar, MD and Döhner, Hartmut, MD and Dörken, Bernd, MD and Engel, Nicole, MD and Topp, Max, MD and Klutmann, Susanne, MD and Amthauer, Holger, MD and Bockisch, Andreas, MD and Kluge, Regine, MD and Kratochwil, Clemens, MD and Schober, Otmar, MD and Greil, Richard, MD and Andreesen, Reinhard, MD and Kneba, Michael, MD and Pfreundschuh, Michael, MD and Stein, Harald, MD and Eich, Hans Theodor, MD and Müller, Rolf-Peter, MD and Dietlein, Markus, MD and Borchmann, Peter, MD and Diehl, Volker, MD and on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, and the Arbeitsgemeinschaft Medikamentöse Tumortherapie and Arbeitsgemeinschaft Medikamentose and Swiss Grp Clinical Canc Res and German Hodgkin Study Grp and Swiss Group for Clinical Cancer Research and German Hodgkin Study Group and Arbeitsgemeinschaft Medikamentöse Tumortherapie
The Lancet (British edition), ISSN 0140-6736, 05/2012, Volume 379, Issue 9828, pp. 1791 - 1799
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Histology | Radiation therapy | Lymphoma | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
by Skoetz, Nicole and Will, Andrea and Monsef, Ina and Brillant, Corinne and Engert, Andreas and von Tresckow, Bastian and Skoetz, Nicole
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, pp. CD007941 - CD007941
Procarbazine | Vinblastine | Hodgkin Disease | Antineoplastic Combined Chemotherapy Protocols | Etoposide | Prednisone | Doxorubicin | Vincristine | Disease Progression | Randomized Controlled Trials as Topic | Dacarbazine | Hodgkin Lymphoma | Cyclophosphamide | Blood disorders | Bleomycin | Hodgkin’s lymphoma | Child health | Medicine General & Introductory Medical Sciences | Haematological malignancies | Cancer | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Bleomycin - administration & dosage | Bleomycin - adverse effects | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights